TMED9 and glioblastoma: Elevated TMED9 expression was also identified as a risk factor for poor DSS in GBM, HNSC, KIRC, kidney renal papillary cell carcinoma (KIRP), LGG, and UVM, while serving as a protective factor in ACC.